New Study: "Comprehensive Evaluation of a 1021-Gene Panel in FFPE and Liquid Biopsy for Analytical and Clinical Use"

30 June, 2025

New Study: “Comprehensive Evaluation of a 1021-Gene Panel in FFPE and Liquid Biopsy for Analytical and Clinical Use”

We are pleased to share the latest publication featuring Prime DX in the International Journal of Molecular Sciences “Comprehensive Evaluation of a 1021-Gene Panel in FFPE and Liquid Biopsy for Analytical and Clinical Use” (Meintani et al., 2025).

In a validation study involving more than 1,300 patients, Prime DX demonstrated exceptional analytical performance and strong clinical relevance in solid tumors.

More than 50% of patients across variant types had targetable findings (on-label/off-label) across a wide spectrum of variants: SNVs, indels, CNVs & fusion.
High sensitivity & specificity
Strong concordance of Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) with established methods.
Strong concordance of Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) with established methods.

Prime DX supports precision oncology, enabling comprehensive molecular profiling for both targeted therapies and immunotherapy decisions.

Read the full publication here: https://genekor.com/wp-content/uploads/2025/06/Comprehensive-Evaluation-of-a-1021-Gene-Panel-in-FFPE-and-Liquid-Biopsy-for-Analytical-and-Clinical-Use.pdf